OBJECTIVES: We tested the hypothesis that a C-reactive protein and ferritin-based systemic inflammation contingency table can track mortality risk in pediatric severe sepsis. DESIGN: Prospective cohort study. SETTING: Tertiary PICU. PATIENTS: Children with 100 separate admission episodes of severe sepsis were enrolled. INTERVENTIONS: Blood samples were attained on day 2 of sepsis and bi-weekly for biomarker batch analysis. A 2 × 2 contingency table using C-reactive protein and ferritin thresholds was developed. MEASUREMENTS AND MAIN RESULTS: A C-reactive protein of 4.08 mg/dL and a ferritin of 1,980 ng/mL were found to be optimal cutoffs for outcome prediction at first sampling (n = 100) using the Youden index. PICU mortality was increased in the "high-risk" C-reactive protein greater than or equal to 4.08 mg/dL and ferritin greater than or equal to 1,980 ng/mL category (6/13 [46.15%]) compared with the "intermediate-risk" C-reactive protein greater than or equal to 4.08 mg/dL and ferritin less than 1,980 ng/mL or C-reactive protein less than 4.08 mg/dL and ferritin greater than or equal to 1,980 ng/mL categories (2/43 [4.65%]), and the "low-risk" C-reactive protein less than 4.08 mg/dL and ferritin less than 1,980 ng/mL category (0/44 [0%]) (odds ratio, 36.43 [95% CI, 6.16-215.21]). The high-risk category was also associated with the development of immunoparalysis (odds ratio, 4.47 [95% CI, 1.34-14.96]) and macrophage activation syndrome (odds ratio, 24.20 [95% CI, 5.50-106.54]). Sixty-three children underwent sequential blood sampling; those who were initially in the low-risk category (n = 24) and those who subsequently migrated (n = 19) to the low-risk category all survived, whereas those who remained in the "at-risk" categories had increased mortality (7/20 [35%]; p < 0.05). CONCLUSIONS: A C-reactive protein- and ferritin-based contingency table effectively assessed mortality risk. Reduction in systemic inflammation below a combined threshold C-reactive protein of 4.08 mg/dL and ferritin of 1,980 ng/mL appeared to be a desired response in children with severe sepsis.
OBJECTIVES: We tested the hypothesis that a C-reactive protein and ferritin-based systemic inflammation contingency table can track mortality risk in pediatric severe sepsis. DESIGN: Prospective cohort study. SETTING: Tertiary PICU. PATIENTS: Children with 100 separate admission episodes of severe sepsis were enrolled. INTERVENTIONS: Blood samples were attained on day 2 of sepsis and bi-weekly for biomarker batch analysis. A 2 × 2 contingency table using C-reactive protein and ferritin thresholds was developed. MEASUREMENTS AND MAIN RESULTS: A C-reactive protein of 4.08 mg/dL and a ferritin of 1,980 ng/mL were found to be optimal cutoffs for outcome prediction at first sampling (n = 100) using the Youden index. PICU mortality was increased in the "high-risk" C-reactive protein greater than or equal to 4.08 mg/dL and ferritin greater than or equal to 1,980 ng/mL category (6/13 [46.15%]) compared with the "intermediate-risk" C-reactive protein greater than or equal to 4.08 mg/dL and ferritin less than 1,980 ng/mL or C-reactive protein less than 4.08 mg/dL and ferritin greater than or equal to 1,980 ng/mL categories (2/43 [4.65%]), and the "low-risk" C-reactive protein less than 4.08 mg/dL and ferritin less than 1,980 ng/mL category (0/44 [0%]) (odds ratio, 36.43 [95% CI, 6.16-215.21]). The high-risk category was also associated with the development of immunoparalysis (odds ratio, 4.47 [95% CI, 1.34-14.96]) and macrophage activation syndrome (odds ratio, 24.20 [95% CI, 5.50-106.54]). Sixty-three children underwent sequential blood sampling; those who were initially in the low-risk category (n = 24) and those who subsequently migrated (n = 19) to the low-risk category all survived, whereas those who remained in the "at-risk" categories had increased mortality (7/20 [35%]; p < 0.05). CONCLUSIONS: A C-reactive protein- and ferritin-based contingency table effectively assessed mortality risk. Reduction in systemic inflammation below a combined threshold C-reactive protein of 4.08 mg/dL and ferritin of 1,980 ng/mL appeared to be a desired response in children with severe sepsis.
Authors: Randy Q Cron; Edward M Behrens; Bita Shakoory; Athimalaipet V Ramanan; Walter W Chatham Journal: J Rheumatol Date: 2015-07 Impact factor: 4.666
Authors: H D Volk; P Reinke; D Krausch; H Zuckermann; K Asadullah; J M Müller; W D Döcke; W J Kox Journal: Intensive Care Med Date: 1996-10 Impact factor: 17.440
Authors: Richard S Hotchkiss; Katherine C Chang; Mitchell H Grayson; Kevin W Tinsley; Benjamin S Dunne; Christopher G Davis; Dale F Osborne; Irene E Karl Journal: Proc Natl Acad Sci U S A Date: 2003-05-07 Impact factor: 11.205
Authors: Jacqueline Unsinger; Jacquelyn S McDonough; Leonard D Shultz; Thomas A Ferguson; Richard S Hotchkiss Journal: J Leukoc Biol Date: 2009-04-15 Impact factor: 4.962
Authors: Joseph A Carcillo; Kate K Kernan; Christopher M Horvat; Dennis W Simon; Rajesh K Aneja Journal: Pediatr Crit Care Med Date: 2020-05 Impact factor: 3.624
Authors: Christopher M Horvat; Jamie Bell; Sajel Kantawala; Alicia K Au; Robert S B Clark; Joseph A Carcillo Journal: Clin Pediatr (Phila) Date: 2019-03-31 Impact factor: 1.168
Authors: Teresa B Kortz; James Nyirenda; Dumizulu Tembo; Kristina Elfving; Kimberly Baltzell; Gama Bandawe; Philip J Rosenthal; Sarah B Macfarlane; Wilson Mandala; Tonney S Nyirenda Journal: Am J Trop Med Hyg Date: 2019-12 Impact factor: 2.345
Authors: Alicia M Alcamo; Diana Pang; Dalia A Bashir; Joseph A Carcillo; Trung C Nguyen; Rajesh K Aneja Journal: J Pediatr Intensive Care Date: 2018-11-20
Authors: Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain Journal: Pediatr Blood Cancer Date: 2019-07-24 Impact factor: 3.167
Authors: Andrea Picchianti Diamanti; Maria Manuela Rosado; Claudio Pioli; Giorgio Sesti; Bruno Laganà Journal: Int J Mol Sci Date: 2020-05-08 Impact factor: 5.923